替格瑞洛增强腺苷生物学效应的研究进展
发布时间：2018-12-12 07:36
【摘要】：替格瑞洛是一个起效迅速、作用强效、与P2Y12受体可逆结合的抗血小板聚集药物。替格瑞洛不同于其他噻吩并吡啶类P2Y12受体拮抗剂的临床获益,与P2Y12受体拮抗以外的作用密切相关。近来研究发现,替格瑞洛可以通过抑制腺苷转运体ENT1,特别是在缺血和组织损伤处,提高血浆中腺苷的浓度,增加腺苷介导的生物学效应。本文将对替格瑞洛增加腺苷介导的生物学效应作一综述。
[Abstract]:Tigrilol is a rapid and potent anti-platelet aggregation drug that reversibly binds to P2Y12 receptors. Tigrillo is different from other thiophene pyridine P2Y12 receptor antagonists in clinical benefits, and is closely related to the role of P2Y12 receptor antagonism. Recently it has been found that tigrilol can increase the concentration of adenosine in plasma and increase the biological effect mediated by adenosine by inhibiting adenosine transporter ENT1, especially at ischemic and tissue injury sites. This review reviews the biological effects of tigrilol on adenosine-mediated increase.
【作者单位】： 哈尔滨医科大学附属第一医院心血管重症监护病房;哈尔滨医科大学病理生理教研室;
【分类号】：R963
本文编号：2374194
[Abstract]:Tigrilol is a rapid and potent anti-platelet aggregation drug that reversibly binds to P2Y12 receptors. Tigrillo is different from other thiophene pyridine P2Y12 receptor antagonists in clinical benefits, and is closely related to the role of P2Y12 receptor antagonism. Recently it has been found that tigrilol can increase the concentration of adenosine in plasma and increase the biological effect mediated by adenosine by inhibiting adenosine transporter ENT1, especially at ischemic and tissue injury sites. This review reviews the biological effects of tigrilol on adenosine-mediated increase.
【作者单位】： 哈尔滨医科大学附属第一医院心血管重症监护病房;哈尔滨医科大学病理生理教研室;
【分类号】：R963
【相似文献】
相关期刊论文 前2条
1 甄子英;;替格瑞洛治疗急性冠状动脉综合征疗效观察[J];齐齐哈尔医学院学报;2014年13期
2 师树田;聂绍平;;替格瑞洛在急性冠状动脉综合征患者中的应用[J];中国介入心脏病学杂志;2014年07期
相关硕士学位论文 前1条
1 陈佳彬;阿司匹林、氯吡格雷抵抗及替格瑞洛研究进展[D];重庆医科大学;2014年
，本文编号：2374194
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2374194.html
最近更新
教材专著
